In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.

@article{Elsby2011InVR,
  title={In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.},
  author={Robert Elsby and L Fox and David M. Stresser and Mark Layton and Caroline J Butters and Pradeep Kumar Sharma and Veronica Smith and Dominic D Surry},
  journal={European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences},
  year={2011},
  volume={43 1-2},
  pages={41-9}
}
Methotrexate is the most commonly used drug to treat rheumatoid arthritis. Since clinical efficacy studies in rheumatoid arthritis are conducted on a background of methotrexate therapy, it is necessary to assess the potential of rheumatoid arthritis candidate drugs to perpetrate a drug-drug interaction (DDI) with methotrexate during development. Consequently, we need to identify the regulatory in vitro studies required to facilitate this assessment. We therefore reviewed the literature to… CONTINUE READING
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…